{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:17:20Z","timestamp":1791839840770,"version":"4.3.4"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R01HS027375"],"award-info":[{"award-number":["5R01HS027375"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002537"],"award-info":[{"award-number":["UL1TR002537"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>People with cystic fibrosis (CF) are at increased risk for bronchiectasis, and several reports suggest that CF carriers may also be at higher risk for developing bronchiectasis. The purpose of this study was to determine if CF carriers are at risk for more severe courses or complications of bronchiectasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using MarketScan data (2001\u20132021), we built a cohort consisting of 105 CF carriers with bronchiectasis and 300 083 controls with bronchiectasis but without a CF carrier diagnosis. We evaluated if CF carriers were more likely to be hospitalized for bronchiectasis. In addition, we examined if CF carriers were more likely to be infected with Pseudomonas aeruginosa or nontuberculous mycobacteria (NTM) or to have filled more antibiotic prescriptions. We considered regression models for incident and rate outcomes that controlled for age, sex, smoking status, and comorbidities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The odds of hospitalization were almost 2.4 times higher (95% CI, 1.116\u20135.255) for CF carriers with bronchiectasis when compared with non\u2013CF carriers with bronchiectasis. The estimated odds of being diagnosed with a Pseudomonas infection for CF carriers vs noncarriers was about 4.2 times higher (95% CI, 2.417\u20137.551) and 5.4 times higher (95% CI, 3.398\u20138.804) for being diagnosed with NTM. The rate of distinct antibiotic fill dates was estimated to be 2 times higher for carriers as compared with controls (95% CI, 1.735\u20132.333), and the rate ratio for the total number of days of antibiotics supplied was estimated as 2.8 (95% CI, 2.290\u20133.442).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CF carriers with bronchiectasis required more hospitalizations and more frequent administration of antibiotics as compared with noncarriers. Given that CF carriers were also more likely to be diagnosed with Pseudomonas and NTM infections, CF carriers with bronchiectasis may have a phenotype more resembling CF-related bronchiectasis than non-CF bronchiectasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae024","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T15:50:07Z","timestamp":1705593007000},"source":"Crossref","is-referenced-by-count":12,"title":["Cystic Fibrosis Carrier States Are Associated With More Severe Cases of Bronchiectasis"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-8966","authenticated-orcid":false,"given":"Aaron C","family":"Miller","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan M","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Iowa , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Oregon Health and Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E","family":"Cavanaugh","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Iowa , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud H","family":"Abou Alaiwa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Hornick","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Stoltz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-5898","authenticated-orcid":false,"given":"Philip M","family":"Polgreen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"2024022214294767300_ofae024-B1","doi-asserted-by":"crossref","first-page":"e0263695","DOI":"10.1371\/journal.pone.0263695","article-title":"Development of a core outcome set and outcome measurement set for physiotherapy trials in adults with bronchiectasis (COS-PHyBE study): a protocol","volume":"17","author":"Hamzeh","year":"2022","journal-title":"PLoS One"},{"key":"2024022214294767300_ofae024-B2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur Respir J"},{"key":"2024022214294767300_ofae024-B3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","article-title":"Bronchiectasis","volume":"4","author":"Chalmers","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2024022214294767300_ofae024-B4","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.rmed.2006.03.012","article-title":"Characterisation of the onset and presenting clinical features of adult bronchiectasis","volume":"100","author":"King","year":"2006","journal-title":"Respir Med"},{"key":"2024022214294767300_ofae024-B5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.108.4.955","article-title":"Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort","volume":"108","author":"Nicotra","year":"1995","journal-title":"Chest"},{"key":"2024022214294767300_ofae024-B6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1164\/rccm.201303-0411CI","article-title":"Non\u2013cystic fibrosis bronchiectasis","volume":"188","author":"McShane","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2024022214294767300_ofae024-B7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.01899-2015","article-title":"Clinical phenotypes in adult patients with bronchiectasis","volume":"47","author":"Aliberti","year":"2016","journal-title":"Eur Respir J"},{"key":"2024022214294767300_ofae024-B8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.prrv.2010.10.010","article-title":"Differences and similarities in non\u2013cystic fibrosis bronchiectasis between developing and affluent countries","volume":"12","author":"Kapur","year":"2011","journal-title":"Paediatr Respir Rev"},{"key":"2024022214294767300_ofae024-B9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1378\/chest.11-2209","article-title":"Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007","volume":"142","author":"Seitz","year":"2012","journal-title":"Chest"},{"key":"2024022214294767300_ofae024-B10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3389\/fimmu.2020.00522","article-title":"Bronchiectasis in primary antibody deficiencies: a multidisciplinary approach","volume":"11","author":"Wall","year":"2020","journal-title":"Front Immunol"},{"key":"2024022214294767300_ofae024-B11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.prrv.2012.02.001","article-title":"The immunological investigation of a child with chronic wet cough","volume":"13","author":"Mehr","year":"2012","journal-title":"Paediatr Respir Rev"},{"key":"2024022214294767300_ofae024-B12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1479972317709649","article-title":"Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013","volume":"14","author":"Weycker","year":"2017","journal-title":"Chron Respir Dis"},{"key":"2024022214294767300_ofae024-B13","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"2024022214294767300_ofae024-B14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pcl.2008.10.014","article-title":"Bronchiectasis in children","volume":"56","author":"Redding","year":"2009","journal-title":"Pediatr Clin North Am"},{"key":"2024022214294767300_ofae024-B15","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"2024022214294767300_ofae024-B16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"key":"2024022214294767300_ofae024-B17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N Engl J Med"},{"key":"2024022214294767300_ofae024-B18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/10906570152742317","article-title":"A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes","volume":"5","author":"Castellani","year":"2001","journal-title":"Genet Test"},{"key":"2024022214294767300_ofae024-B19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00018-016-2393-9","article-title":"Cystic fibrosis: a clinical view","volume":"74","author":"Castellani","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"2024022214294767300_ofae024-B20","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1073\/pnas.1914912117","article-title":"Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis\u2013related conditions","volume":"117","author":"Miller","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024022214294767300_ofae024-B21","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1164\/rccm.200909-1434OC","article-title":"Cystic fibrosis transmembrane conductance regulator channel dysfunction in non\u2013cystic fibrosis bronchiectasis","volume":"181","author":"Bienvenu","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2024022214294767300_ofae024-B22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccm.2012.02.002","article-title":"Bronchiectasis and nontuberculous mycobacterial disease","volume":"33","author":"Griffith","year":"2012","journal-title":"Clin Chest Med"},{"key":"2024022214294767300_ofae024-B23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1164\/rccm.200805-686OC","article-title":"Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome","volume":"178","author":"Kim","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2024022214294767300_ofae024-B24"},{"key":"2024022214294767300_ofae024-B25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-med-042120-020148","article-title":"Clinical phenotypes of cystic fibrosis carriers","volume":"73","author":"Polgreen","year":"2022","journal-title":"Annu Rev Med"},{"key":"2024022214294767300_ofae024-B26","doi-asserted-by":"crossref","first-page":"ofy219","DOI":"10.1093\/ofid\/ofy219","article-title":"CFTR heterozygotes are at increased risk of respiratory infections: a population-based study","volume":"5","author":"Polgreen","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2024022214294767300_ofae024-B27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.0009-9163.2004.00265.x","article-title":"Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations?","volume":"65","author":"Casals","year":"2004","journal-title":"Clin Genet"},{"key":"2024022214294767300_ofae024-B28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s004390100467","article-title":"CFTR gene mutations\u2014including three novel nucleotide substitutions\u2014and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease","volume":"108","author":"Tzetis","year":"2001","journal-title":"Hum Genet"},{"key":"2024022214294767300_ofae024-B29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000484750","article-title":"CFTR gene mutations in adults with disseminated bronchiectasis","volume":"5","author":"Girodon","year":"1997","journal-title":"Eur J Hum Genet"},{"key":"2024022214294767300_ofae024-B30","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024022214294767300_ofae024-B31","doi-asserted-by":"crossref","first-page":"106627","DOI":"10.1016\/j.rmed.2021.106627","article-title":"Factors associated with \u201cfrequent exacerbator\u201d phenotype in children with bronchiectasis: the first report on children from the Australian Bronchiectasis Registry","volume":"188","author":"Kapur","year":"2021","journal-title":"Respir Med"},{"key":"2024022214294767300_ofae024-B32","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1183\/09031936.96.09081601","article-title":"Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa","volume":"9","author":"Evans","year":"1996","journal-title":"Eur Respir J"},{"key":"2024022214294767300_ofae024-B33","first-page":"1602","article-title":"A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2024022214294767300_ofae024-B34","doi-asserted-by":"crossref","first-page":"1701953","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"Ara\u00fajo","year":"2018","journal-title":"Eur Respir J"},{"key":"2024022214294767300_ofae024-B35","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/cid\/ciac117","article-title":"The rapid reduction of infection-related visits and antibiotic use among people with cystic fibrosis after starting elexacaftor-tezacaftor-ivacaftor","volume":"75","author":"Miller","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024022214294767300_ofae024-B36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ppul.10079","article-title":"Mucociliary clearance in cystic fibrosis","volume":"33","author":"Robinson","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"2024022214294767300_ofae024-B37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1513\/pats.200703-042BR","article-title":"Mucociliary clearance as an outcome measure for cystic fibrosis clinical research","volume":"4","author":"Donaldson","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"2024022214294767300_ofae024-B38","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/ppul.24858","article-title":"Changes in mucociliary clearance over time in children with cystic fibrosis","volume":"55","author":"Laube","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2024022214294767300_ofae024-B39","doi-asserted-by":"crossref","first-page":"18703","DOI":"10.1073\/pnas.1422091112","article-title":"Ph modulates the activity and synergism of the airway surface liquid antimicrobials \u03b2-defensin-3 and LL-37","volume":"111","author":"Abou Alaiwa","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024022214294767300_ofae024-B40","doi-asserted-by":"crossref","first-page":"11614","DOI":"10.1073\/pnas.97.21.11614","article-title":"The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing","volume":"97","author":"Zabner","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024022214294767300_ofae024-B41","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood.2021014699","article-title":"Neutrophil dysfunction in the pathogenesis of cystic fibrosis","volume":"139","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"2024022214294767300_ofae024-B42","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/resp.13047","article-title":"Mucoactive agents for chronic, non\u2013cystic fibrosis lung disease: a systematic review and meta-analysis","volume":"22","author":"Tarrant","year":"2017","journal-title":"Respirology"},{"key":"2024022214294767300_ofae024-B43","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/thoraxjnl-2014-205587","article-title":"Inhaled mannitol for non\u2013cystic fibrosis bronchiectasis: a randomised, controlled trial","volume":"69","author":"Bilton","year":"2014","journal-title":"Thorax"},{"key":"2024022214294767300_ofae024-B44","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1164\/ajrccm.159.6.9809074","article-title":"Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis","volume":"159","author":"Daviskas","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2024022214294767300_ofae024-B45","author":"Cystic Fibrosis Foundation"},{"key":"2024022214294767300_ofae024-B46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations\u2014correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Hum Mutat"},{"key":"2024022214294767300_ofae024-B47","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jcf.2015.02.012","article-title":"Should diffuse bronchiectasis still be considered a CFTR -related disorder?","volume":"14","author":"Bergougnoux","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2024022214294767300_ofae024-B48","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s004390050897","article-title":"Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease","volume":"103","author":"Bombieri","year":"1998","journal-title":"Hum Genet"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae024\/56209173\/ofae024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/2\/ofae024\/56740959\/ofae024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/2\/ofae024\/56740959\/ofae024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T19:00:23Z","timestamp":1708628423000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae024\/7571485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae024","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,1,17]]},"article-number":"ofae024"}}